Altamont Pharma Acquisition registered today with the SEC to offer 10 million units at $10 each. A unit consists of one share of common stock and one warrant. Each warrant entitles the holder to purchase one half-share of common stock. No exercise price is listed for these warrants in the company’s S-1 filing.
The new SPAC said it will target companies engaged in healthcare innovation.
The company is led by President, CEO and Chairman Mark Pearson, founder and CEO of biotech investment firm Altamont Pharma.
The SPAC has applied for a Nasdaq listing under ALTPU. Read more.
